243 related articles for article (PubMed ID: 26577434)
1. [Antibiotic therapy of intra-abdominal infections in the era of multiresistance].
Eckmann C
Chirurg; 2016 Jan; 87(1):26-33. PubMed ID: 26577434
[TBL] [Abstract][Full Text] [Related]
2. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
Syue LS; Chen YH; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
[TBL] [Abstract][Full Text] [Related]
3. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: current experience in a teaching hospital.
Shree N; Arora BS; Mohil RS; Kasana D; Biswal I
Indian J Pathol Microbiol; 2013; 56(4):388-92. PubMed ID: 24441227
[TBL] [Abstract][Full Text] [Related]
4. The Challenge of Antimicrobial Resistance in Managing Intra-Abdominal Infections.
Sartelli M; Catena F; di Saverio S; Ansaloni L; Coccolini F; Tranà C; Kirkby-Bott J
Surg Infect (Larchmt); 2015 Jun; 16(3):213-20. PubMed ID: 25831090
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.
Eckmann C; Dryden M; Montravers P; Kozlov R; Sganga G
Eur J Med Res; 2011 Mar; 16(3):115-26. PubMed ID: 21486724
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
7. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Kaye KS; Pogue JM
Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
[TBL] [Abstract][Full Text] [Related]
8. New antibiotic agents: problems and prospects.
Weber DJ; Rutala WA
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
[TBL] [Abstract][Full Text] [Related]
9. Eravacycline for the treatment of intra-abdominal infections.
Bassetti M; Righi E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1575-84. PubMed ID: 25251475
[TBL] [Abstract][Full Text] [Related]
10. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
[TBL] [Abstract][Full Text] [Related]
11. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
12. Essentials for selecting antimicrobial therapy for intra-abdominal infections.
Blot S; De Waele JJ; Vogelaers D
Drugs; 2012 Apr; 72(6):e17-32. PubMed ID: 22480338
[TBL] [Abstract][Full Text] [Related]
13. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
14. Novel multidrug resistant microorganisms in critically ill: a potential threat.
Grossi PA; Tebini A; Dalla Gasperina D
Minerva Anestesiol; 2015 Jan; 81(1):52-64. PubMed ID: 24594917
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous bacterial peritonitis due to multidrug resistant bacteria: are the current guidelines outdated?
Fiore M
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):731. PubMed ID: 27111388
[No Abstract] [Full Text] [Related]
17. Epidemiology and Risk Factors for Isolation of Multi-Drug-Resistant Organisms in Patients with Complicated Intra-Abdominal Infections.
Labricciosa FM; Sartelli M; Abbo LM; Barbadoro P; Ansaloni L; Coccolini F; Catena F
Surg Infect (Larchmt); 2018 Apr; 19(3):264-272. PubMed ID: 29298133
[TBL] [Abstract][Full Text] [Related]
18. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections--are they applicable today?
Caínzos M
Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():9-18. PubMed ID: 19040462
[TBL] [Abstract][Full Text] [Related]
19. Intra-abdominal infections: model of antibiotic stewardship in an era with limited antimicrobial options.
Leone S; Stefani S; Venditti M; Grossi P; Colizza S; De Gasperi A; Scaglione F; Sganga G; Esposito S;
Int J Antimicrob Agents; 2011 Sep; 38(3):271-2. PubMed ID: 21782394
[No Abstract] [Full Text] [Related]
20. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
